资源描述：
《不同剂量的贝伐单抗联合传统一线化疗方案治疗转移性结直肠癌的毒性和有效性的分析——基于随机临床对照试验的meta分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、AbstractABSTRACTObjective：Althoughtheapplicationofbevacizumabtotraditionalchemotherapyschemeplaysasignificantroleinfirst-linetreatmentofadvancedstagemalignanttumor,randomizedcontrolledtrials(RCTs)ofapplyingbevacizumabinpatientswithmetastaticcolorectalcancerhaverep
2、ortedconflictingresults.Andtheefficacyandtoxicityofaddingdifferentdosagesbevacizumabtochemotherapyregimenformetastaticcolorectalcancerarestillunclear.Therefore,ourresearchgroupconductedthismeta-analysistoassesstheefficacyandtoxicityofbevacizumabatdifferentdosagesa
3、ddedtofirst-linechemotherapyschemeformetastaticcolorectaladenocarcinomapatients.Method：WesearchedPubMed/MEDLINE,ASCO,EMBASEandCochranedatabasesetctoselectthequalifiedstudies.Result：Finally,eighttrials,contained3265patients,weremeettherequirement.Thepooledoutcomeme
4、asurementsincludedprogression-freesurvival(PFS),overallsurvival(OS),overallresponserate(ORR),grade3-5toxicitiesandtreatment-relatedmortality.Hazardratios(HR)andriskratio(RR)withtheircorresponding95%confidenceintervals(95%CI)wereusedforthemeta-analysis.Asaresult,th
5、eapplicationofbevacizumabtofirst-linechemotherapytreatmentsignificantlyprolongedPFS(fixedeffect:HR=0.50;95%CI:0.42-0.60;P<0.001)andincreasedOS(fixedeffect:HR:0.67;95%CI:0.60-0.76;P<0.001)aswellasORR(fixedeffect:RR=1.41;95%CI=1.20–1.65;P<0.001)at5mg/kg,butthismeta-
6、analysisrevealednostatisticaladvantageatdoseof7.5mg/kg.Ontoxicity,theriskofhypertensionwassignificantlyincreasedinbevacizumabgroupat5mg/kg,aswellasproteinuriaanddiarrheaat7.5mg/kg.However,theproportionoftreatment-relatedmortalitywasnotincreasedatbothdosages.Conclu
7、sion：Thismeta-analysissuggestedthatlow-dosagebevacizumabnotonlyincreasedtheOS,PFSandORRformetastaticcolorectaladenocarcinomaIII万方数据Abstractpatients,butalsohadlowrisksofsomeadverseevents(AEs)comparedwithhigh-dosagebevacizumab.Therefore,bevacizumabtreatmentwith5mg/k
8、gshouldbetakenintoconsiderationwhenselectingtheapplicableup-to-datetargetedtherapy.Keywords：metastaticcolorectalcarcinoma,bevacizumab,meta-analysis,toxi
